

Javier A Menendez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1788867/javier-a-menendez-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

327
papers

22,187
citations

68
h-index

140
g-index

342
ext. papers

24,742
ext. citations

5
avg, IF

6.87
L-index

#	Paper	IF	Citations
327	Metformin and Breast Cancer: Where Are We Now?. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	4
326	Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.. <i>American Journal of Cancer Research</i> , 2022 , 12, 839-851	4.4	
325	Fatty acid synthase: a druggable driver of breast cancer brain metastasis.. <i>Expert Opinion on Therapeutic Targets</i> , 2022 , 1-18	6.4	0
324	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. <i>Cell Death and Disease</i> , 2021 , 12, 977	9.8	2
323	Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	7
322	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprogramming in estrogen receptor-positive breast cancer. <i>Nature Communications</i> , 2021 , 12, 1920	17.4	5
321	Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression. <i>Journal of Hepatology</i> , 2021 ,	13.4	2
320	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
319	Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs. <i>PLoS Computational Biology</i> , 2021 , 17, e1008408	5	3
318	Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview. <i>Biomolecules</i> , 2021 , 11,	5.9	3
317	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
316	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. <i>EMBO Molecular Medicine</i> , 2021 , 13, e13929	12	0
315	Polyphenols in olive oil: the importance of phenolic compounds in the chemical composition of olive oil 2021 , 111-122		2
314	Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin.. <i>Pharmaceuticals</i> , 2021 , 15,	5.2	1
313	Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
312	Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. <i>Viruses</i> , 2020 , 12,	6.2	48
311	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	25

310	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6	3
309	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11217	12	13
308	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. <i>Aging</i> , 2020 , 12, 8-34	5.6	49
307	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. <i>Aging</i> , 2020 , 12, 4794-4814	5.6	21
306	Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19. <i>Aging</i> , 2020 , 12, 8760-8765	5.6	31
305	Systemic overexpression of C-C motif chemokine ligand 2 promotes metabolic dysregulation and premature death in mice with accelerated aging. <i>Aging</i> , 2020 , 12, 20001-20023	5.6	2
304	Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer. <i>Aging</i> , 2020 , 12, 24671-24692	5.6	2
303	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. <i>Aging</i> , 2020 , 12, 21057-21075	5.6	1
302	Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity. <i>Biomolecules</i> , 2020 , 10,	5.9	7
301	Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors. <i>Cytokine</i> , 2020 , 126, 154923	4	7
300	Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 374-387	6.1	8
299	Chemokine C-C motif ligand 2 overexpression drives tissue-specific metabolic responses in the liver and muscle of mice. <i>Scientific Reports</i> , 2020 , 10, 11954	4.9	6
298	Structure-Biological Activity Relationships of Extra-Virgin Olive Oil Phenolic Compounds: Health Properties and Bioavailability. <i>Antioxidants</i> , 2020 , 9,	7.1	16
297	Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
296	Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology. <i>Frontiers in Oncology</i> , 2020 , 10, 620641	5.3	1
295	Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018. <i>Nutrients</i> , 2019 , 11,	6.7	59
294	Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. <i>OncolImmunology</i> , 2019 , 8, e1633235	7.2	39
293	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. <i>Food and Chemical Toxicology</i> , 2019 , 131, 110529	4.7	8

292	A multiscale model of epigenetic heterogeneity-driven cell fate decision-making. <i>PLoS Computational Biology</i> , 2019 , 15, e1006592	5	19
291	Stratification of cancer and diabetes based on circulating levels of formate and glucose. <i>Cancer & Metabolism</i> , 2019 , 7, 3	5.4	10
290	The Allele of rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. <i>Frontiers in Oncology</i> , 2019 , 9, 193	5.3	10
289	The moonlighting RNA-binding activity of cytosolic serine hydroxymethyltransferase contributes to control compartmentalization of serine metabolism. <i>Nucleic Acids Research</i> , 2019 , 47, 4240-4254	20.1	12
288	Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 1555-1566	6.9	8
287	The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. <i>Food and Chemical Toxicology</i> , 2019 , 128, 35-45	4.7	20
286	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
285	Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. <i>Metabolism: Clinical and Experimental</i> , 2019 , 99, 81-89	12.7	17
284	Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A. <i>Nutrients</i> , 2019 , 11,	6.7	16
283	Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation. <i>Food and Chemical Toxicology</i> , 2019 , 132, 110645	4.7	8
282	Abstract 2746: Stat3 labels a subpopulation of reactive astrocytes required for brain metastasis 2019 ,		2
281	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. <i>Aging</i> , 2019 , 11, 2874-2888	5.6	18
280	clinical trials for anti-aging therapies. <i>Aging</i> , 2019 , 11, 6591-6601	5.6	2
279	Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer. <i>Anti-Cancer Drugs</i> , 2019 , 30, 1067-1070	2.4	2
278	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
277	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. <i>Carcinogenesis</i> , 2019 , 40, 27-40	4.6	9
276	Assessment of extracellular matrix-related biomarkers in patients with lower extremity artery disease. <i>Journal of Vascular Surgery</i> , 2018 , 68, 1135-1142.e6	3.5	3
275	Silibinin is a direct inhibitor of STAT3. <i>Food and Chemical Toxicology</i> , 2018 , 116, 161-172	4.7	35

274	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. <i>Carcinogenesis</i> , 2018 , 39, 601-613	4.6	35
273	Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism. <i>Oncogene</i> , 2018 , 37, 963-970	9.2	65
272	Differential inhibitory effect of a pyrazolopyran compound on human serine hydroxymethyltransferase-amino acid complexes. <i>Archives of Biochemistry and Biophysics</i> , 2018 , 653, 71-79	4.1	7
271	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. <i>Aging Cell</i> , 2018 , 17, e12772	9.9	43
270	Mitostemness. <i>Cell Cycle</i> , 2018 , 17, 918-926	4.7	10
269	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. <i>Nature Medicine</i> , 2018 , 24, 1024-1035	50.5	156
268	Epigenetic regulation of cell fate reprogramming in aging and disease: A predictive computational model. <i>PLoS Computational Biology</i> , 2018 , 14, e1006052	5	15
267	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. <i>Oncotarget</i> , 2018 , 9, 35687-35704	3.3	34
266	Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. <i>Oncotarget</i> , 2018 , 9, 33043-33049	3.3	8
265	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. <i>Frontiers in Endocrinology</i> , 2018 , 9, 657	5.7	64
264	Plasma Energy-Balance Metabolites Discriminate Asymptomatic Patients with Peripheral Artery Disease. <i>Mediators of Inflammation</i> , 2018 , 2018, 2760272	4.3	8
263	Fatty acid synthase regulates estrogen receptor- β signaling in breast cancer cells. <i>Oncogenesis</i> , 2017 , 6, e299	6.6	51
262	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. <i>Cell Cycle</i> , 2017 , 16, 1022-1028	4.7	17
261	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. <i>Oncotarget</i> , 2017 , 8, 99223-99236	3.3	8
260	Fatty acid synthase (FASN) as a therapeutic target in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 1001-1016	6.4	120
259	Targeting STAT3 with silibinin to improve cancer therapeutics. <i>Cancer Treatment Reviews</i> , 2017 , 58, 61-69	4.4	57
258	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. <i>Oncology Reports</i> , 2017 , 38, 263-270	3.5	7
257	Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	12

256	Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users. <i>Nutrients</i> , 2017 , 9,	6.7	21
255	Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2017 , 5, 49	5.7	16
254	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. <i>Histology and Histopathology</i> , 2017 , 32, 687-698	1.4	27
253	BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. <i>Oncotarget</i> , 2017 , 8, 35019-35032	3.3	10
252	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. <i>Cell Cycle</i> , 2016 , 15, 3413-3418	4.7	38
251	Metformin targets histone acetylation in cancer-prone epithelial cells. <i>Cell Cycle</i> , 2016 , 15, 3355-3361	4.7	15
250	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
249	Oncometabolic Nuclear Reprogramming of Cancer Stemness. <i>Stem Cell Reports</i> , 2016 , 6, 273-83	8	28
248	Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method. <i>Journal of the American Society for Mass Spectrometry</i> , 2016 , 27, 168-77	3.5	28
247	Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate. <i>Aging</i> , 2016 , 8, 1330-52	5.6	54
246	The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells. <i>Oncoscience</i> , 2016 , 3, 242-257	0.8	16
245	Metformin and cancer: Quo vadis et cui bono?. <i>Oncotarget</i> , 2016 , 7, 54096-54101	3.3	13
244	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. <i>Oncotarget</i> , 2016 , 7, 82185-82199	3.3	11
243	Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. <i>Oncotarget</i> , 2016 , 7, 11959-713	3.3	9
242	Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. <i>Oncotarget</i> , 2016 , 7, 71151-71168	3.3	35
241	Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers. <i>Oncotarget</i> , 2016 , 7, 52974-52992	3.3	24
240	Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. <i>Oncotarget</i> , 2016 , 7, 32006-14	3.3	29
239	Nuclear reprogramming of cancer stem cells: Corrupting the epigenetic code of cell identity with oncometabolites. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1160854	1.2	3

238	Epigenetics and nutrition-related epidemics of metabolic diseases: Current perspectives and challenges. <i>Food and Chemical Toxicology</i> , 2016 , 96, 191-204	4.7	20
237	The acute impact of polyphenols from <i>Hibiscus sabdariffa</i> in metabolic homeostasis: an approach combining metabolomics and gene-expression analyses. <i>Food and Function</i> , 2015 , 6, 2957-66	6.1	20
236	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. <i>Cell Cycle</i> , 2015 , 14, 3527-32	4.7	22
235	Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv090	9.7	9
234	Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus. <i>Clinical and Translational Oncology</i> , 2015 , 17, 581-9	3.6	3
233	Lemon verbena (<i>Lippia citriodora</i>) polyphenols alleviate obesity-related disturbances in hypertrophic adipocytes through AMPK-dependent mechanisms. <i>Phytomedicine</i> , 2015 , 22, 605-14	6.5	53
232	Managing hypertension by polyphenols. <i>Planta Medica</i> , 2015 , 81, 624-9	3.1	14
231	A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting ¹¹¹ In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. <i>Nuclear Medicine and Biology</i> , 2015 , 42, 931-8	2.1	12
230	Pediatric solid organ transplant recipients: transition to home and chronic illness care. <i>Pediatric Transplantation</i> , 2015 , 19, 118-29	1.8	34
229	Mapping of the circulating metabolome reveals βketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. <i>International Journal of Obesity</i> , 2015 , 39, 279-87	5.5	60
228	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. <i>Oncotarget</i> , 2015 , 6, 32317-38	3.3	26
227	Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells. <i>PLoS ONE</i> , 2015 , 10, e0137800	3.7	22
226	Metabolic control of cancer cell stemness: Lessons from iPS cells. <i>Cell Cycle</i> , 2015 , 14, 3801-11	4.7	28
225	Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. <i>Cancer Treatment Reviews</i> , 2015 , 41, 540-6	14.4	98
224	The promiscuous and synergic molecular interaction of polyphenols in bactericidal activity: an opportunity to improve the performance of antibiotics?. <i>Phytotherapy Research</i> , 2015 , 29, 466-73	6.7	25
223	Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. <i>Oncoscience</i> , 2015 , 2, 958-967	0.8	24
222	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer. <i>Oncotarget</i> , 2015 , 6, 7104-22	3.3	12
221	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. <i>Oncotarget</i> , 2015 , 6, 12279-96	3.3	41

220	Heregulin, a new interactor of the telosome/shelterin complex in human telomeres. <i>Oncotarget</i> , 2015 , 6, 39408-21	3.3	4
219	Heregulin, a new regulator of telomere length in human cells. <i>Oncotarget</i> , 2015 , 6, 39422-36	3.3	6
218	The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs. <i>Current Pharmaceutical Design</i> , 2015 , 21, 3644-53	3.3	13
217	Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7529-44	5.6	28
216	Polyphenols and the modulation of gene expression pathways: can we eat our way out of the danger of chronic disease?. <i>Critical Reviews in Food Science and Nutrition</i> , 2014 , 54, 985-1001	11.5	75
215	Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. <i>Lung Cancer</i> , 2014 , 86, 102-4	5.9	21
214	Molecular promiscuity of plant polyphenols in the management of age-related diseases: far beyond their antioxidant properties. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 824, 141-59	3.6	66
213	An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients. <i>Scientific Reports</i> , 2014 , 4, 5743	4.9	2
212	Understanding the role of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia threatening the lower extremities. <i>Vascular Medicine</i> , 2014 , 19, 442-51	3.3	10
211	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. <i>Cell Cycle</i> , 2014 , 13, 1132-44	4.7	54
210	Autophagy is an inflammation-related defensive mechanism against disease. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 824, 43-59	3.6	30
209	Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes. <i>Cell Cycle</i> , 2014 , 13, 358-70	4.7	14
208	Hibiscus sabdariffa extract lowers blood pressure and improves endothelial function. <i>Molecular Nutrition and Food Research</i> , 2014 , 58, 1374-8	5.9	40
207	Energy metabolism and metabolic sensors in stem cells: the metabostem crossroads of aging and cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 824, 117-40	3.6	22
206	Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. <i>Cell Cycle</i> , 2014 , 13, 699-709	4.7	29
205	Metabostemness: a new cancer hallmark. <i>Frontiers in Oncology</i> , 2014 , 4, 262	5.3	76
204	The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential. <i>Frontiers in Oncology</i> , 2014 , 4, 308	5.3	15
203	CCN1 promotes vascular endothelial growth factor secretion through $\alpha 5 \beta 1$ integrin receptors in breast cancer. <i>Journal of Cell Communication and Signaling</i> , 2014 , 8, 23-7	5.2	9

202	Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins. <i>Aging</i> , 2014 , 6, 731-41	5.6	21
201	Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. <i>Oncoscience</i> , 2014 , 1, 803-6	0.8	25
200	Discovery and validation of an INflammatory PROtein-driven GAstic cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. <i>Oncotarget</i> , 2014 , 5, 1942-54	3.3	13
199	Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. <i>Oncotarget</i> , 2014 , 5, 2344-8	3.3	35
198	Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. <i>Oncotarget</i> , 2014 , 5, 8306-16	3.3	76
197	The nutritional phenome of EMT-induced cancer stem-like cells. <i>Oncotarget</i> , 2014 , 5, 3970-82	3.3	55
196	Cell cycle regulation by the nutrient-sensing mammalian target of rapamycin (mTOR) pathway. <i>Methods in Molecular Biology</i> , 2014 , 1170, 113-44	1.4	72
195	Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient. <i>Anticancer Research</i> , 2014 , 34, 4323-7	2.3	16
194	A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. <i>AIDS Research and Therapy</i> , 2013 , 10, 11	3	11
193	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. <i>Food and Chemical Toxicology</i> , 2013 , 60, 360-8	4.7	44
192	Multifunctional targets of dietary polyphenols in disease: a case for the chemokine network and energy metabolism. <i>Food and Chemical Toxicology</i> , 2013 , 51, 267-79	4.7	50
191	Identification of active compounds in vegetal extracts based on correlation between activity and HPLC-MS data. <i>Food Chemistry</i> , 2013 , 136, 392-9	8.5	12
190	Metabolic stress in infected cells may represent a therapeutic target for human immunodeficiency virus infection. <i>Medical Hypotheses</i> , 2013 , 81, 125-30	3.8	6
189	The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. <i>Cell Cycle</i> , 2013 , 12, 207-18	4.7	65
188	The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. <i>Cell Cycle</i> , 2013 , 12, 1166-79	4.7	126
187	Autophagy in stem cells. <i>Autophagy</i> , 2013 , 9, 830-49	10.2	209
186	The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. <i>Scientific Reports</i> , 2013 , 3, 2469	4.9	81
185	Mitochondrial dysfunction: a basic mechanism in inflammation-related non-communicable diseases and therapeutic opportunities. <i>Mediators of Inflammation</i> , 2013 , 2013, 135698	4.3	104

184	Ubiquitous transgenic overexpression of C-C chemokine ligand 2: a model to assess the combined effect of high energy intake and continuous low-grade inflammation. <i>Mediators of Inflammation</i> , 2013 , 2013, 953841	4.3	10
183	Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). <i>Cell Cycle</i> , 2013 , 12, 225-45	4.7	42
182	Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. <i>PLoS ONE</i> , 2013 , 8, e77281	3.7	137
181	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. <i>Scientific Reports</i> , 2013 , 3, 2560	4.9	63
180	Metformin: a cheap and well-tolerated drug that provides benefits for viral infections. <i>HIV Medicine</i> , 2013 , 14, 233-40	2.7	13
179	Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. <i>Cell Cycle</i> , 2013 , 12, 3471-7	4.7	32
178	Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. <i>Cell Cycle</i> , 2013 , 12, 555-78	4.7	113
177	Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. <i>Cell Cycle</i> , 2013 , 12, 3390-404	4.7	57
176	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. <i>Scientific Reports</i> , 2013 , 3, 2459	4.9	56
175	Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. <i>Cell Cycle</i> , 2013 , 12, 3109-24	4.7	76
174	Serine79-phosphorylated acetyl-CoA carboxylase, a downstream target of AMPK, localizes to the mitotic spindle poles and the cytokinesis furrow. <i>Cell Cycle</i> , 2013 , 12, 1639-41	4.7	14
173	Synchronous solid neuroendocrine breast carcinoma and abdominal lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2013 , 5, 459-462	2.6	3
172	Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. <i>Oncotarget</i> , 2013 , 4, 1484-95	3.3	29
171	Uptake and metabolism of olive oil polyphenols in human breast cancer cells using nano-liquid chromatography coupled to electrospray ionization-time of flight-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012 , 898, 69-77	3.2	26
170	Synergism of plant-derived polyphenols in adipogenesis: perspectives and implications. <i>Phytomedicine</i> , 2012 , 19, 253-61	6.5	100
169	Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. <i>Investigational New Drugs</i> , 2012 , 30, 846-52	4.3	10
168	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. <i>International Journal of Oncology</i> , 2012 , 41, 1128-38	4.4	43
167	Metformin is synthetically lethal with glucose withdrawal in cancer cells. <i>Cell Cycle</i> , 2012 , 11, 2782-92	4.7	101

166	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. <i>Scientific Reports</i> , 2012 , 2, 964	4.9	51
165	Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis. <i>Cell Cycle</i> , 2012 , 11, 4211-21	4.7	17
164	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. <i>Cell Cycle</i> , 2012 , 11, 865-70	4.7	31
163	Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/107 and miR-122 and prevent diet-induced fatty liver disease in hyperlipidemic mice. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012 , 1820, 894-9	4	94
162	Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals. <i>Rejuvenation Research</i> , 2012 , 15, 3-21	2.6	34
161	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-546.2	4.2	2783
160	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. <i>Cell Cycle</i> , 2012 , 11, 974-89	4.7	87
159	Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. <i>Aging</i> , 2012 , 4, 480-98	5.6	93
158	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. <i>Oncotarget</i> , 2012 , 3, 1600-14	3.3	60
157	Polo-like kinase 1 directs the AMPK-mediated activation of myosin regulatory light chain at the cytokinetic cleavage furrow independently of energy balance. <i>Cell Cycle</i> , 2012 , 11, 2422-6	4.7	14
156	Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). <i>Cell Cycle</i> , 2012 , 11, 4020-32	4.7	104
155	Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. <i>British Journal of Cancer</i> , 2012 , 106, 1406-14	8.7	36
154	Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. <i>Cell Cycle</i> , 2012 , 11, 1235-46	4.7	50
153	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. <i>Oncology Reports</i> , 2012 , 27, 1887-92 ^{3.5}	3.5	3
152	Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. <i>Aging</i> , 2012 , 4, 393-401	5.6	90
151	One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin. <i>Aging</i> , 2012 , 4, 894-8	5.6	17
150	Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. <i>Oncotarget</i> , 2012 , 3, 395-8	3.3	120
149	Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. <i>Drug Resistance Updates</i> , 2011 , 14, 212-23	23.2	51

148	Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 407, 412-9	3.4	40
147	Serum fatty acid synthase concentration is increased in patients with hepatitis viral infection and may assist in the prediction of liver steatosis. <i>Journal of Clinical Virology</i> , 2011 , 51, 199-201	14.5	16
146	Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib. <i>Breast Cancer Research</i> , 2011 , 13, 401	8.3	3
145	Metformin: multi-faceted protection against cancer. <i>Oncotarget</i> , 2011 , 2, 896-917	3.3	238
144	Gerosuppressant metformin: less is more. <i>Aging</i> , 2011 , 3, 348-62	5.6	50
143	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbixim) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. <i>International Journal of Cancer</i> , 2011 , 127, 1455-63	4.4	10
142	Continuous administration of polyphenols from aqueous rooibos (<i>Aspalathus linearis</i>) extract ameliorates dietary-induced metabolic disturbances in hyperlipidemic mice. <i>Phytomedicine</i> , 2011 , 18, 414-24	6.5	73
141	mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. <i>Cell Cycle</i> , 2011 , 10, 3658-77	4.7	121
140	Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs). <i>Cell Cycle</i> , 2011 , 10, 3140-52	4.7	29
139	The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 355-64	4.4	139
138	Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 241-5	4.4	5
137	Direct antitumour activity of zoledronic acid: preclinical and clinical data. <i>Clinical and Translational Oncology</i> , 2011 , 13, 148-55	3.6	14
136	Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma. <i>Journal of Surgical Oncology</i> , 2011 , 104, 106-9	2.8	5
135	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. <i>Journal of Cellular Physiology</i> , 2011 , 226, 52-7	7	24
134	Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbixim) efficacy in KRAS wild-type tumor cells. <i>Journal of Cellular Biochemistry</i> , 2011 , 112, 10-29	4.7	34
133	Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. <i>Cell Cycle</i> , 2011 , 10, 3871-85	4.7	150
132	Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3. <i>International Journal of Oncology</i> , 2011 , 38, 1533-47	4.4	19
131	Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response. <i>Cell Cycle</i> , 2011 , 10, 1499-501	4.7	68

130	Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. <i>Cell Cycle</i> , 2011 , 10, 1295-302	4.7	38
129	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGF β Induced oncomiR miRNA-181a. <i>Cell Cycle</i> , 2011 , 10, 1144-51	4.7	97
128	Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 284-90	5	8
127	Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. <i>Aging</i> , 2011 , 3, 1063-77	5.6	59
126	The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. <i>Oncology Reports</i> , 2011 , 25, 135-40	3.5	33
125	Quantitative and functional influence of surround luminance on the letter contrast sensitivity function. <i>Ophthalmic and Physiological Optics</i> , 2010 , 30, 188-99	4.1	5
124	Thyroid hormone responsive Spot 14 increases during differentiation of human adipocytes and its expression is down-regulated in obese subjects. <i>International Journal of Obesity</i> , 2010 , 34, 487-99	5.5	21
123	Discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the 'self (stem cell)-seeding' nature of breast cancer disease?. <i>Annals of Oncology</i> , 2010 , 21, 901-902	10.3	2
122	Metformin against TGF β Induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. <i>Cell Cycle</i> , 2010 , 9, 4461-8	4.7	183
121	Extracellular fatty acid synthase: a possible surrogate biomarker of insulin resistance. <i>Diabetes</i> , 2010 , 59, 1506-11	0.9	38
120	Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. <i>Annals of Oncology</i> , 2010 , 21, 187-9	10.3	48
119	Metformin: a pharmacological approach integrating hyperinsulinemia breast cancer at the molecular, cellular clinical levels. <i>Avances En Diabetología</i> , 2010 , 26, 79-94		
118	Prediction of extra virgin olive oil varieties through their phenolic profile. Potential cytotoxic activity against human breast cancer cells. <i>Journal of Agricultural and Food Chemistry</i> , 2010 , 58, 9942-55	5.7	72
117	Pharmacological mimicking of caloric restriction elicits epigenetic reprogramming of differentiated cells to stem-like self-renewal states. <i>Rejuvenation Research</i> , 2010 , 13, 519-26	2.6	14
116	Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. <i>Cell Cycle</i> , 2010 , 9, 1057-64	4.7	181
115	Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010 , 1801, 381-91	5	112
114	Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 27-33	3.4	54
113	Olive oil and health: summary of the II international conference on olive oil and health consensus report, Ja \acute{n} and C \acute{o} doba (Spain) 2008. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010 , 20, 284-94	4.5	383

112	Polyphenols in Olive Oil 2010 , 167-175		8
111	Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. <i>Cell Cycle</i> , 2010 , 9, 3831-3838	4.7	147
110	Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. <i>Current Molecular Medicine</i> , 2010 , 10, 674-91	2.5	49
109	Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). <i>International Journal of Oncology</i> , 2010 , 37, 669-78	4.4	40
108	Qualitative screening of phenolic compounds in olive leaf extracts by hyphenated liquid chromatography and preliminary evaluation of cytotoxic activity against human breast cancer cells. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 397, 643-54	4.4	95
107	Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss. <i>Nutrition and Metabolism</i> , 2010 , 7, 14	4.6	10
106	Characterization and quantification of phenolic compounds of extra-virgin olive oils with anticancer properties by a rapid and resolutive LC-ESI-TOF MS method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 51, 416-29	3.5	119
105	Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection. <i>BMC Gastroenterology</i> , 2010 , 10, 92	3	18
104	Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies. <i>International Journal of Oncology</i> , 2010 , 36, 107-15	4.4	6
103	Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. <i>Cell Cycle</i> , 2010 , 9, 3807-14	4.7	103
102	Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. <i>Clinical Chemistry</i> , 2009 , 55, 425-38	5.5	140
101	The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. <i>Cell Cycle</i> , 2009 , 8, 88-96	4.7	203
100	The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. <i>Annals of Oncology</i> , 2009 , 20, 592-5	10.3	44
99	Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. <i>Cell Cycle</i> , 2009 , 8, 1633-6	4.7	49
98	Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009 , 47, 1097-9	5.9	6
97	AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. <i>Cell Cycle</i> , 2009 , 8, 3679-83	4.7	60
96	Mitotic kinase dynamics of the active form of AMPK (phospho-AMPK α Thr172) in human cancer cells. <i>Cell Cycle</i> , 2009 , 8, 788-91	4.7	44
95	The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. <i>Cell Cycle</i> , 2009 , 8, 2385-98	4.7	77

94	If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, e207-9; author reply e210	2.2	28
93	A 2-D-HPLC-CE platform coupled to ESI-TOF-MS to characterize the phenolic fraction in olive oil. <i>Electrophoresis</i> , 2009 , 30, 2688-701	3.6	29
92	Direct characterization of aqueous extract of Hibiscus sabdariffa using HPLC with diode array detection coupled to ESI and ion trap MS. <i>Journal of Separation Science</i> , 2009 , 32, 3441-8	3.4	75
91	mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). <i>Clinical and Translational Oncology</i> , 2009 , 11, 455-9	3.6	51
90	Characterization of isomers of oleuropein aglycon in olive oils by rapid-resolution liquid chromatography coupled to electrospray time-of-flight and ion trap tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2009 , 23, 51-9	2.2	43
89	Val1483Ile in FASN gene is linked to central obesity and insulin sensitivity in adult white men. <i>Obesity</i> , 2009 , 17, 1755-61	8	14
88	Tentative characterization of novel phenolic compounds in extra virgin olive oils by rapid-resolution liquid chromatography coupled with mass spectrometry. <i>Journal of Agricultural and Food Chemistry</i> , 2009 , 57, 11140-7	5.7	39
87	AMPK-sensed cellular energy state regulates the release of extracellular Fatty Acid Synthase. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 378, 488-93	3.4	19
86	The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 380, 638-43	3.4	22
85	Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. <i>International Journal of Oncology</i> , 2009 , 35, 1369-76	4.4	17
84	Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. <i>PLoS ONE</i> , 2009 , 4, e6251	3.7	177
83	Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. <i>International Journal of Oncology</i> , 2009 , 34, 12-21	1	13
82	ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations. <i>Clinical Genetics</i> , 2008 , 73, 465-73	4	17
81	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. <i>Cell Proliferation</i> , 2008 , 41, 59-85	7.9	145
80	Anti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO). <i>BMC Cancer</i> , 2008 , 8, 377	4.8	88
79	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. <i>Annals of Oncology</i> , 2008 , 19, 1097-109	10.3	38
78	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling 2008 ,		1
77	Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. <i>Breast Cancer Research and Treatment</i> , 2008 , 109, 471-9	4.4	86

76	Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?. <i>Clinical and Translational Oncology</i> , 2008 , 10, 30-4	3.6	15
75	An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value. <i>Clinical and Translational Oncology</i> , 2008 , 10, 219-26	3.6	
74	BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. <i>Molecular Carcinogenesis</i> , 2008 , 47, 157-63	5	51
73	The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis. <i>Journal of Cellular Biochemistry</i> , 2008 , 105, 1147-52	4.7	22
72	Her-2/neu-induced "cytokine signature" in breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 617, 311-9	3.6	14
71	Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays. <i>International Journal of Molecular Medicine</i> , 2008 , 22, 433-9	4.4	56
70	Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. <i>Oncology Reports</i> , 2008 , 20, 1369-74	3.5	79
69	Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. <i>Nature Reviews Cancer</i> , 2007 , 7, 763-77	31.3	1887
68	Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. <i>Differentiation</i> , 2007 , 75, 819-30	3.5	29
67	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. <i>BMC Cancer</i> , 2007 , 7, 80	4.8	132
66	Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2496-8; author reply 2499	2.2	5
65	Testing the efficacy of antiangiogenic agents in advanced neuroendocrine tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2624; author reply 2624-5	2.2	
64	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. <i>Oncology Reports</i> , 2007 , 18, 973	3.5	5
63	Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin) by transcriptionally inhibiting HER2 super-expression occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells 2007 , 31, 769		10
62	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). <i>International Journal of Molecular Medicine</i> , 2007 ,	4.4	9
61	Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. <i>European Journal of Cancer</i> , 2007 , 43, 1117-24	7.5	71
60	Mapping protein-protein interactions for the yeast ABC transporter Ycf1p by integrated split-ubiquitin membrane yeast two-hybrid analysis. <i>Molecular Cell</i> , 2007 , 26, 15-25	17.6	87
59	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). <i>International Journal of Molecular Medicine</i> , 2007 , 20, 3-10	4.4	54

58	Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. <i>International Journal of Oncology</i> , 2007 , 31, 769-76	1	37
57	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. <i>Oncology Reports</i> , 2007 , 18, 973-80	3.5	35
56	Mediterranean diet, olive oil and cancer. <i>Clinical and Translational Oncology</i> , 2006 , 8, 15-21	3.6	80
55	HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". <i>Clinical and Translational Oncology</i> , 2006 , 8, 812-20	3.6	55
54	A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells. <i>Molecular Carcinogenesis</i> , 2006 , 45, 795-804	5	28
53	RESPONSE: Re: Effect of Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 718-720	9.7	2
52	Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?. <i>Endocrinology</i> , 2006 , 147, 4056-66	4.8	91
51	Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?. <i>Current Pharmaceutical Biotechnology</i> , 2006 , 7, 483-93	2.6	142
50	Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9). <i>Current Pharmaceutical Biotechnology</i> , 2006 , 7, 495-502	2.6	72
49	Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3735-46	2.2	62
48	A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. <i>European Journal of Cancer</i> , 2006 , 42, 2425-32	7.5	88
47	DNA topoisomerase II(TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: In vitro evidence for a functional amplicon involving FAS, Her-2/neu and TOP2A genes. <i>International Journal of Molecular Medicine</i> , 2006 , 18, 1081	4.4	
46	Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2006 , 9, 346-57	3.8	73
45	The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. <i>International Journal of Gynecological Cancer</i> , 2006 , 16, 219-21	3.5	28
44	DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. <i>International Journal of Molecular Medicine</i> , 2006 , 18, 1081-7	4.4	10
43	Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage 2005 , 26, 649		2
42	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival 2005 , 26, 1507		1
41	RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. <i>International Journal of Molecular Medicine</i> , 2005 , 15, 33	4.4	7

40	Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. <i>Annals of Oncology</i> , 2005 , 16, 1253-67	10.3	120
39	Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis. <i>Medical Hypotheses</i> , 2005 , 64, 337-41	3.8	22
38	Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?. <i>Medical Hypotheses</i> , 2005 , 64, 342-9	3.8	55
37	Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. <i>Medical Hypotheses</i> , 2005 , 64, 997-1001	3.8	60
36	Obesity, fatty acid synthase, and cancer: serendipity or forgotten causal linkage?. <i>Molecular Genetics and Metabolism</i> , 2005 , 84, 293-5	3.7	15
35	Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors?. <i>Experimental Biology and Medicine</i> , 2005 , 230, 151-4	3.7	24
34	Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. <i>European Journal of Cancer Prevention</i> , 2005 , 14, 263-70	2	73
33	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. <i>Annals of Oncology</i> , 2005 , 16, 359-71	10.3	158
32	A novel CYR61-triggered 'CYR61-alphaVbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. <i>Oncogene</i> , 2005 , 24, 761-79	9.2	134
31	AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. <i>Oncogene</i> , 2005 , 24, 3759-73	9.2	84
30	In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. <i>Journal of Cellular Biochemistry</i> , 2005 , 94, 1-4	4.7	69
29	Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF). <i>Journal of Cellular Biochemistry</i> , 2005 , 94, 1-4	4.7	27
28	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. <i>International Journal of Cancer</i> , 2005 , 115, 19-35	7.5	88
27	Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1611-5	9.7	30
26	Growth and molecular interactions between tamoxifen and trastuzumab. <i>Clinical Cancer Research</i> , 2005 , 11, 3597; author reply 3597-9	12.9	
25	Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. <i>Drug News and Perspectives</i> , 2005 , 18, 375-85		61
24	RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. <i>International Journal of Molecular Medicine</i> , 2005 , 15, 33-40	4.4	20
23	Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. <i>International Journal of Oncology</i> , 2005 , 26, 649-59	1	6

22	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. <i>International Journal of Oncology</i> , 2005 , 26, 1507-15	1	9
21	Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. <i>Annals of Oncology</i> , 2004 , 15, 1719-21	10.3	23
20	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF- κ B 2004 , 24, 591		14
19	Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 10715-20	11.5	264
18	Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. <i>Oncogene</i> , 2004 , 23, 4945-58	9.2	31
17	Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). <i>Breast Cancer Research and Treatment</i> , 2004 , 84, 183-95	4.4	63
16	Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2004 , 86, 125-37	4.4	40
15	Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor	7.5	20
14	Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. <i>Molecular Carcinogenesis</i> , 2004 , 41, 164-78	5	65
13	Ω 6 polyunsaturated fatty acid linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. <i>Oncology Reports</i> , 2004 , 11, 1241	3.5	4
12	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF- κ B. <i>International Journal of Oncology</i> , 2004 , 24, 591-608	1	41
11	Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. <i>Oncology Reports</i> , 2004 , 11, 1241-52	3.5	41
10	Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. <i>International Journal of Oncology</i> , 2004 , 24, 1369-83	1	25
9	Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. <i>Oncology Reports</i> , 2004 , 12, 411-22	3.5	28
8	Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2004 , 52, 414-26	4	36
7	The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. <i>Endocrine-Related Cancer</i> , 2003 , 10, 141-52	5.7	95
6	Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2002 , 72, 203-19	4.4	65
5	Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet 2002 , 21, 745		2

4	Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. <i>European Journal of Cancer</i> , 2001 , 37, 402-13	7.5	111
3	Solid neuroendocrine breast carcinomas: Incidence, clinico-pathological features and immunohistochemical profiling. <i>Oncology Reports</i> , 1994 , 20, 1369	3.5	4
2	Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: Relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2 1992 ,		3
1	Growth and molecular interactions of the anti-EGFR antibody Cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer 1992 , 33, 1165		3